| scholarly article | Q13442814 |
| P2093 | author name string | Evgeny Krupitsky | |
| Alexander Grinenko | |||
| Andrey Burakov | |||
| Igor Dunaevsky | |||
| Rick Strassman | |||
| Tatyana Romanova | |||
| P2860 | cites work | A SELF-RATING DEPRESSION SCALE | Q28201088 |
| Antidepressant effects of ketamine in depressed patients | Q29617327 | ||
| Ketamine psychedelic therapy (KPT): a review of the results of ten years of research | Q30538308 | ||
| Human psychopharmacology of N,N-dimethyltryptamine | Q34395371 | ||
| Ibogaine neurotoxicity assessment: electrophysiological, neurochemical, and neurohistological methods | Q34435923 | ||
| Medication development of ibogaine as a pharmacotherapy for drug dependence. | Q40850975 | ||
| Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations | Q42545370 | ||
| Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale | Q43842193 | ||
| Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans | Q43842201 | ||
| Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial | Q44855735 | ||
| 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action. | Q51372570 | ||
| LSD in the Treatment of Alcoholics* | Q59831058 | ||
| Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study | Q69264445 | ||
| Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence | Q71226356 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heroin dependence | Q18558272 |
| P304 | page(s) | 273-283 | |
| P577 | publication date | 2002-12-01 | |
| P1433 | published in | Journal of Substance Abuse Treatment | Q15762042 |
| P1476 | title | Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up | |
| P478 | volume | 23 |
| Q34246188 | 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects |
| Q92062542 | A Review of Nonanesthetic Uses of Ketamine |
| Q46847604 | A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment |
| Q47197626 | A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study |
| Q34674320 | Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions |
| Q43842140 | Acute and post-acute behavioral and psychological effects of salvinorin A in humans |
| Q26746137 | Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years |
| Q39202806 | Case report: efficacy and tolerability of ketamine in opioid-refractory cancer pain |
| Q34535259 | Clinical applications of hallucinogens: A review |
| Q57174889 | Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review |
| Q36935431 | Future of God in recovery from drug addiction |
| Q38040996 | Glutamate mechanisms underlying opiate memories |
| Q55059681 | Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use. |
| Q44539047 | Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision |
| Q22252593 | Hallucinogens: An update |
| Q33937677 | Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users |
| Q36685572 | Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders |
| Q28386419 | Heroin self-administration: II. CNS gene expression following withdrawal and cue-induced drug-seeking behavior |
| Q36418016 | Ketamine : from medicine to misuse |
| Q38837851 | Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior |
| Q38351502 | Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? |
| Q89091482 | Psychedelics Promote Structural and Functional Neural Plasticity |
| Q58782625 | Psychological features of abstinent heroin users before and after rehabilitation in Saint Petersburg, Russia |
| Q93048063 | Repurposing Potential of Ketamine: Opportunities and Challenges |
| Q26779981 | Role of ketamine in acute postoperative pain management: a narrative review |
| Q34631390 | Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence |
| Q47151084 | Subanesthetic ketamine decreases the incentive-motivational value of reward-related cues |
| Q42034477 | Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia. |
| Q53439351 | The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions. |
| Q22251018 | The neurobiology of psychedelic drugs: implications for the treatment of mood disorders |
| Q28257248 | The subjective experience of acute, experimentally-induced Salvia divinorum inebriation |
| Q33880853 | Therapeutic infusions of ketamine: do the psychoactive effects matter? |
| Q38023813 | Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses |
Search more.